Table 4.
Impact of BRAF V600E/RAS or TERT promoter mutation or their coexistence on clinicopathologic outcomes of PTC
| Characteristic | No Mutation | BRAF/RAS Mutation Only | TERT Mutation Only | BRAF/RAS+TERT Mutation | |||
|---|---|---|---|---|---|---|---|
| No. (Percent) | No. (Percent) | P | No. (Percent) | P | No. (Percent) | P | |
| Sample size | 109 | 240 | 5 | 34 | |||
|
| |||||||
| Age at diagnosis, Median (IQR), y | 46 (33–59) | 45 (34–54) | .34 | 49 (37–68) | .51 | 66 (58–72) | <.001 |
|
| |||||||
| Sex, male | 27/109 (24.8) | 62/240 (25.8) | .94 | 0/5 (0) | .34 | 13/34 (38.2) | .13 |
|
| |||||||
| Multifocality | 53/103 (51.5) | 107/237 (45.1) | .34 | 0/5 (0) | .06 | 14/34 (41.2) | .33 |
|
| |||||||
| Tumor size, Median (IQR), cm | 2.9 (1.9–4) | 2.4 (1.5–3.5) | .09 | 4 (3.0–5.0) | .68 | 3 (2.4–4.6) | .12 |
|
| |||||||
| Extrathyroidal invasion | 17/104 (16.3) | 74/232 (31.9) | .005 | 1/5 (20) | 1 | 19/34 (55.9) | <.001 |
|
| |||||||
| AJCC tumor stage | |||||||
| stage I | 66/108 (61.1) | 147/239 (61.5) | .07 | 3/5 (60) | .31 | 5/34 (14.7) | <.001 |
| stage II | 18/108 (16.7) | 19/239 (7.9) | 1/5 (20) | 3/34 (8.8) | |||
| stage III | 19/108 (17.6) | 53/239 (22.2) | 0/5 (0) | 11/34 (32.3) | |||
| stage IV | 5/108 (4.6) | 20/239 (8.4) | 1/5 (20) | 15/34 (44.1) | |||
| stage III + stage IV | 24/108 (22.2) | 73/239 (30.6) | .12 | 1/5 (20) | 1 | 26/34 (76.4) | <.001 |
|
| |||||||
| AJCC_T | |||||||
| T1 | 31/107 (29.0) | 78/240 (32.5) | .08 | 1/5 (20) | .06 | 5/34 (14.7) | <.001 |
| T2 | 46/107 (43.0) | 74/240 (30.8) | 2/5 (40) | 8/34 (23.5) | |||
| T3 | 30/107 (28.0) | 82/240 (34.2) | 1/5 (20) | 13/34 (38.2) | |||
| T4 | 0/107 (0) | 6/240 (2.5) | 1/5 (20) | 8/34 (23.5) | |||
| T3 + T4 | 30/107 (28.0) | 88/240 (36.7) | .14 | 2/5 (40) | .62 | 21/34 (61.7) | <.001 |
|
| |||||||
| AJCC_N, N1 | 38/92 (41.3) | 107/218 (49.1) | .26 | 3/5 (60) | .65 | 19/33 (57.6) | .21 |
|
| |||||||
| AJCC_M, M1 | 0/54 (0) | 3/146 (2.1) | .56 | 0/4 (0) | 1 | 4/21 (19.0) | .005 |
|
| |||||||
| Distant metastasis | 1/50 (2) | 8/126 (6.3) | .45 | 0/4 (0) | 1 | 7/21 (33.3) | <.001 |
|
| |||||||
| Tumor recurrence | 6/87 (6.9) | 25/189 (13.2) | .15 | 1/5 (20) | .33 | 13/25 (52) | <.001 |
|
| |||||||
| Mortality rate | 3/108 (2.8) | 5/232 (2.2) | .71 | 1/5 (20) | .17 | 5/34 (14.7) | .019 |
|
| |||||||
| Total follow-up, Median (IQR), month | 30 (17–46) | 35 (19–60) | .18 | 13 (6–28) | .15 | 42 (17–52) | .23 |
IQR, interquartile range; AJCC, American Joint Committee on Cancer. AJCC_M refers to distant metastasis status at the diagnosis of thyroid cancer; M1, presence of metastasis. The group “Distant metastasis” below the group “AJCC_M” in the table refers to any distant metastasis, including distant metastasis at the diagnosis and distant metastasis discovered during the follow-up time, i.e., metastatic recurrence.